Matthew C Konerman1, John J Lazarus2, Richard L Weinberg2, Ravi V Shah3, Michael Ghannam, Scott L Hummel2, James R Corbett2,4, Edward P Ficaro2,4, Keith D Aaronson2, Monica M Colvin2, Todd M Koelling2, Venkatesh L Murthy2,4. 1. Division of Cardiovascular Medicine, Department of Internal Medicine (M.C.K., J.J.L., R.L.W., M.G., S.L.H., J.R.C., K.D.A., M.M.C., T.M.K., V.L.M.) mkonerma@med.umich.edu. 2. Division of Cardiovascular Medicine, Department of Internal Medicine (M.C.K., J.J.L., R.L.W., M.G., S.L.H., J.R.C., K.D.A., M.M.C., T.M.K., V.L.M.). 3. University of Michigan, Ann Arbor. Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston (R.V.S.). 4. Division of Nuclear Medicine, Department of Radiology (J.R.C., E.P.F., V.L.M.).
Abstract
BACKGROUND: We evaluated the diagnostic and prognostic value of quantification of myocardial flow reserve (MFR) with positron emission tomography (PET) in orthotopic heart transplant patients. METHODS AND RESULTS: We retrospectively identified orthotopic heart transplant patients who underwent rubidium-82 cardiac PET imaging. The primary outcome was the composite of cardiovascular death, acute coronary syndrome, coronary revascularization, and heart failure hospitalization. Cox regression was used to evaluate the association of MFR with the primary outcome. The relationship of MFR and cardiac allograft vasculopathy severity in patients with angiography within 1 year of PET imaging was assessed using Spearman rank correlation and logistic regression. A total of 117 patients (median age, 60 years; 71% men) were identified. Twenty-one of 62 patients (34%) who underwent angiography before PET had cardiac allograft vasculopathy. The median time from orthotopic heart transplant to PET imaging was 6.4 years (median global MFR, 2.31). After a median of 1.4 years, 22 patients (19%) experienced the primary outcome. On an unadjusted basis, global MFR (hazard ratio, 0.22 per unit increase; 95% confidence interval, 0.09-0.50; P<0.001) and stress myocardial blood flow (hazard ratio, 0.48 per unit increase; 95% confidence interval, 0.29-0.79; P=0.004) were associated with the primary outcome. Decreased MFR independently predicted the primary outcome after adjustment for other variables. In 42 patients who underwent angiography within 12 months of PET, MFR and stress myocardial blood flow were associated with moderate-severe cardiac allograft vasculopathy (International Society of Heart and Lung Transplantation grade 2-3). CONCLUSIONS: MFR assessed by cardiac rubidium-82 PET imaging is a predictor of cardiovascular events after orthotopic heart transplant and is associated with cardiac allograft vasculopathy severity.
BACKGROUND: We evaluated the diagnostic and prognostic value of quantification of myocardial flow reserve (MFR) with positron emission tomography (PET) in orthotopic heart transplant patients. METHODS AND RESULTS: We retrospectively identified orthotopic heart transplant patients who underwent rubidium-82 cardiac PET imaging. The primary outcome was the composite of cardiovascular death, acute coronary syndrome, coronary revascularization, and heart failure hospitalization. Cox regression was used to evaluate the association of MFR with the primary outcome. The relationship of MFR and cardiac allograft vasculopathy severity in patients with angiography within 1 year of PET imaging was assessed using Spearman rank correlation and logistic regression. A total of 117 patients (median age, 60 years; 71% men) were identified. Twenty-one of 62 patients (34%) who underwent angiography before PET had cardiac allograft vasculopathy. The median time from orthotopic heart transplant to PET imaging was 6.4 years (median global MFR, 2.31). After a median of 1.4 years, 22 patients (19%) experienced the primary outcome. On an unadjusted basis, global MFR (hazard ratio, 0.22 per unit increase; 95% confidence interval, 0.09-0.50; P<0.001) and stress myocardial blood flow (hazard ratio, 0.48 per unit increase; 95% confidence interval, 0.29-0.79; P=0.004) were associated with the primary outcome. Decreased MFR independently predicted the primary outcome after adjustment for other variables. In 42 patients who underwent angiography within 12 months of PET, MFR and stress myocardial blood flow were associated with moderate-severe cardiac allograft vasculopathy (International Society of Heart and Lung Transplantation grade 2-3). CONCLUSIONS: MFR assessed by cardiac rubidium-82 PET imaging is a predictor of cardiovascular events after orthotopic heart transplant and is associated with cardiac allograft vasculopathy severity.
Authors: Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani Journal: Circulation Date: 2002-01-29 Impact factor: 29.690
Authors: S M Hollenberg; L W Klein; J E Parrillo; M Scherer; D Burns; P Tamburro; M Oberoi; M R Johnson; M R Costanzo Journal: Circulation Date: 2001-12-18 Impact factor: 29.690
Authors: Jon A Kobashigawa; Jonathan M Tobis; Randall C Starling; E Murat Tuzcu; Andrew L Smith; Hannah A Valantine; Alan C Yeung; Mandeep R Mehra; Hitoshi Anzai; Brandy T Oeser; Kamal H Abeywickrama; Jane Murphy; Nathalie Cretin Journal: J Am Coll Cardiol Date: 2005-05-03 Impact factor: 24.094
Authors: François Haddad; Prateeti Khazanie; Tobias Deuse; Dana Weisshaar; Jessica Zhou; Chang Wook Nam; Thu A Vu; Fatemeh A Gomari; Mehdi Skhiri; Ana Simos; Ingela Schnittger; Bojan Vrotvec; Sharon A Hunt; William F Fearon Journal: Circ Heart Fail Date: 2012-08-29 Impact factor: 8.790
Authors: Linda D Sharples; Christopher H Jackson; Jayan Parameshwar; John Wallwork; Stephen R Large Journal: Transplantation Date: 2003-08-27 Impact factor: 4.939
Authors: G Vassalli; A Gallino; M Weis; W von Scheidt; L Kappenberger; L K von Segesser; J-J Goy Journal: Eur Heart J Date: 2003-07 Impact factor: 29.983
Authors: Eugenia Raichlin; Jang-Ho Bae; Zain Khalpey; Brooks S Edwards; Walter K Kremers; Alfredo L Clavell; Richard J Rodeheffer; Robert P Frantz; Charanjit Rihal; Amir Lerman; Sudhir S Kushwaha Journal: Circulation Date: 2007-11-19 Impact factor: 29.690
Authors: F G St Goar; F J Pinto; E L Alderman; H A Valantine; J S Schroeder; S Z Gao; E B Stinson; R L Popp Journal: Circulation Date: 1992-03 Impact factor: 29.690
Authors: Olaf M Muehling; Norbert M Wilke; Prasad Panse; Michael Jerosch-Herold; Betsy V Wilson; Robert F Wilson; Leslie W Miller Journal: J Am Coll Cardiol Date: 2003-09-17 Impact factor: 24.094
Authors: Andrew Van Tosh; J Jane Cao; John R Votaw; C David Cooke; Christopher J Palestro; Kenneth J Nichols Journal: J Nucl Cardiol Date: 2021-08-20 Impact factor: 3.872
Authors: Sharon Chih; Aun Yeong Chong; Jordan Bernick; George A Wells; Robert A deKemp; Ross A Davies; Ellamae Stadnick; Derek Y So; Christopher Overgaard; Lisa M Mielniczuk; Rob S B Beanlands Journal: J Nucl Cardiol Date: 2020-01-28 Impact factor: 5.952
Authors: Benjamin C Lee; Jonathan B Moody; Alexis Poitrasson-Rivière; Amanda C Melvin; Richard L Weinberg; James R Corbett; Venkatesh L Murthy; Edward P Ficaro Journal: J Nucl Cardiol Date: 2018-11-07 Impact factor: 5.952
Authors: Uttam M Shrestha; Maria Sciammarella; Miguel Hernandez Pampaloni; Elias H Botvinick; Grant T Gullberg; Teresa DeMarco; Youngho Seo Journal: Int J Cardiovasc Imaging Date: 2020-10-29 Impact factor: 2.357